BioSpace News Archive

Generation Bio Co. announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10th at 4:30 p.m. PST in San Francisco, CA.

Zentalis™ Pharmaceuticals, Inc. announced that on January 3, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 30,625 shares of the Company’s common stock to two newly hired employees.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism pioneering therapies for rare diseases, announced the grant of inducement equity awards outside of the Company’s 2013 Stock Incentive Plan to its newly appointed Chief Commercial Officer, Tsveta Milanova.

Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has finalized the supplement for market authorization request in accordance with the De Novo registration process concerning the company’s RemeOs™ trauma screw, and FDA has now confirmed having received the supplement.

Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced that management will participate at the 41st Annual J.P. Morgan Healthcare Conference taking place in San Francisco, California.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that no action will be taken on the Company’s new drug application (NDA) for vonoprazan, a novel potassium-competitive acid blocker (PCAB), under review as a treatment for erosive esophagitis, on or prior to the current Prescription Drug User Fee Act (PDUFA) target action date of January 11, 2023.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Board-certified hematologist and medical oncologist William T. McGarry, MD has joined the statewide practice.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, announced today that the European Medicines Agency (EMA) validated its Type II Variation application to extend the indication for VOXZOGO® (vosoritide) for injection to treat children with achondroplasia under the age of 2.

Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, announced that Chief Executive Officer Masoud Toloue will be presenting at the 41st Annual J.P. Morgan Healthcare Conference.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces that Gaurav Shah, M.D., Chief Executive Officer, is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 2:15 p.m. PT.